Scientists have discovered that the enzyme TYK2 modifies tau proteins, leading to their accumulation in the brain—a key feature of Alzheimer’s disease and related dementias. By reducing TYK2 activity in animal models, researchers found tau buildup was decreased, suggesting TYK2 inhibitors could be a potential therapeutic pathway.
